updates in the diagnosis & classification of ...haematology.org.my/afh2010/slides/14b.pdfwho...
TRANSCRIPT
![Page 1: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/1.jpg)
Updates in the Diagnosis
& Classification of
Myeloproliferative
Disorders
![Page 2: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/2.jpg)
From Disorder,
Disease to Neoplasm
Jameela Sathar
Ampang Hospital
23 April 2010
![Page 3: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/3.jpg)
The story…
![Page 4: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/4.jpg)
Clinical insights
• 1892 Louis Henri Vaquez
Polycythaemia Vera (PV)
• 1890s Gustav Hueck
Primary Myelofibrosis (PMF)
• 1934 Emil Epstein & Alfred Goedel
Essential Thrombocythaemia (ET)
![Page 5: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/5.jpg)
Myeloproliferative ‘Disorders’William Dameshek 1951
• PV
• ET
• PMF
–Overlap in clinical and laboratory
features
![Page 6: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/6.jpg)
PV, ET, PMF
• ? Separate diseases
• ? Same disease, different manifestations
• ? Combination of both
![Page 7: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/7.jpg)
Clonality• 1967 Fialkow
Polymorphisms at G6PD locus
• 1974 Axelrad, Prchal
Endogenous Erythroid Colony formation
• 1976 Adamson
Single G6PD isoform in red cells, granulocytes and platelets from PV patients
![Page 8: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/8.jpg)
JAK2V617F
• 2005 Vainchenker, Kravolics, Levine
JAK2V617F mutation
• Valine to phenylalanine substitution at
codon 617 of JAK2 on chromosome 9p
• Constitutive kinase activation of
hematopoeitic growth factor receptors
![Page 9: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/9.jpg)
Goldman JM. N Engl J Med 2005;352:1744-1746
![Page 10: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/10.jpg)
JH7 JH4 JH3JH5 JH2 JH1
Cytokine
receptor
binding
Pseudokinase
domainKinase
domain
Exon 12
mutationV617F
JAK2 Domains
JH6
![Page 11: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/11.jpg)
JAK2V617F
• 95% in PV ( JAK2 exon 12 mutation in 5%)
• 50% in ET and PMF
• <3% in MDS
• Not seen in reactive myeloproliferation or
lymphoid disorders
Levine RL, Blood 2006
![Page 12: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/12.jpg)
JAK2 mutation analysis
• Allele-specific PCR assay
• Real-time PCR
• Pyrosequencing
• Restriction enzyme digestion
Levine RL 2006; James C 2006;
Baxter EJ 2005; Jones AV 2005
![Page 13: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/13.jpg)
? 1Mutation, 3Diseases
• Gene dosage
– high neutrophil allele burden – higher Hct and
WBC, lower platelet, splenomegaly
• Homozygosity
– homozygous JAK2V617F favours PV over ET
• Inherited MPD alleles
• Cooperating mutations eg. 20q-
Tiedt R 2007; Xing S, Blood 2008
![Page 14: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/14.jpg)
Other mutations that activate
JAK2 signaling
• MPLW515L/K
• 5-10% of JAK2 negative ET and PMF
• Higher platelet counts
• Marked fibrosis
• JAK2 exon 12
• Only identified in JAK2V617F negative PV
Beer P, Blood 2008
Percy MJ 2007
![Page 15: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/15.jpg)
WHO Classification
![Page 16: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/16.jpg)
Before JAK2V617F
![Page 17: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/17.jpg)
Chronic Myeloproliferative ‘Diseases’ WHO 2001
• Chronic Myeloid Leukemia (CML)
• Chronic Neutrophilic Leukemia (CNL)
• Chronic Eosinophilic Leukemia/ hypereosinophilic syndrome (CEL/ HES)
• PV
• Chronic idiopathic myelofibrosis (CIMF)
• ET
• MPD, unclassifiable
![Page 18: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/18.jpg)
Discovery of JAK2V617F
![Page 19: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/19.jpg)
Myeloproliferative ‘Neoplasms’WHO 2008
• CML, Bcr-Abl positive
• CNL
• PV
• Primary Myelofibrosis
• ET
• CEL-NOS
• Mastocytosis
• Myeloproliferative Neoplasm, unclassifiable
![Page 20: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/20.jpg)
Polycythaemia Vera
![Page 21: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/21.jpg)
WHO 2008- PV
Major criteria
1. Hb >18.5(M);
>16.5(F) or other
RCV
2. Presence of
JAK2V617F or exon
12 mutation
Minor criteria
1. BM trilineage
myeloproliferation
2. Subnormal serum
epo level
3. EEC growth
Diagnosis of PV:
• both major + 1 minor or
• 1st major + 2 minor
![Page 22: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/22.jpg)
WHO 2001- PV
A1: RCM >25%
A2: no 20 erythrocytosis
A3: splenomegaly
A4: clonal abn; non-bcr-
abl
A5: EEC formation in vitro
B1: thrombocytosis >400
B2: WBC >12
B3. PV BM changes
B4: low serum epo level
Diagnosis: First 2A + one
other A or 2B
![Page 23: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/23.jpg)
WHO 2008 PV criteria
• Omits:
– splenomegaly
– platelet and leucocyte count
– no secondary cause for erythrocytosis
• New:
– JAK2V617F mutation
– Hb>18.5 (M); Hb>16.5 (F) = absolute erythrocytosis
– Importance of BM changes
![Page 24: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/24.jpg)
Erythrocytosis
• Sets PV apart from other MPDs
• No evidence to support substitution of Hb values for red cell mass
• Normal Hb or Hct ≠ normal red cell mass
• Haemodilution from hypersplenism; iron deficiency anaemia
![Page 25: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/25.jpg)
True
erythrocytosis
Hb >18.5 g/dL
(n= 31)
Apparent
Erythrocytosi
s
Hb <18.5 g/dL
(n= 49)
True
erythrocytosis
11 (35%) 20 (65%)
Apparent
erythrocytosis
7 (14%) 42 (76%)RC
M a
nd
PV
WHO Hb guidelines (M)
Johansson PL, BJH 2005
![Page 26: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/26.jpg)
True
erythrocytosis
Hb >16.5 g/dL
(n=46)
Apparent
Erythrocytosi
s
Hb <16.5 g/dL
(n=17)
True
erythrocytosis
29 (63%) 17 (37%)
Apparent
erythrocytosis
6 (35%) 11 (65%)RC
M a
nd
PV
WHO Hb guidelines (F)
Johansson PL, BJH 2005
![Page 27: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/27.jpg)
Hematocrit
• Hct ≥60 = absolute erythrocytosis
2 studies: Johansson (2005) and Pearson
(1984)
![Page 28: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/28.jpg)
Red Cell Mass
• Red Cell Mass 51Cr- and Plasma Volume 125I
• Cumbersome, costly and time-consuming
• Mainly to distinguish PV from ET in absence
of high Hct
• Becoming obsolete with JAK2 mutation
![Page 29: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/29.jpg)
Phlebotomy trial
• Absolute erythrocytosis:
– Requiring ≥ 2 phlebotomies
– To reduce Hct to < 45% (M) or < 42% (F)
– 10% Hct rise within 3 months
Spivak JL 2008
![Page 30: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/30.jpg)
JAK2V617F in PV
• >95% of patients with PV
• High negative predictive value in PV
• V617F homozygosity is specific for PV
Scott LM; Blood 2006
![Page 31: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/31.jpg)
JAK2V617F in Budd Chiari
• MPD represent the commonest cause of
Budd Chiari syndrome
• >50% with unexplained Budd Chiari
syndrome are JAK2V617F positive
Janssen HL, J Hepatol 2003;
Patel RK, Gastroenterology 2006;
Kiladjian JJ, Blood 2008
![Page 32: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/32.jpg)
BM morphology
• Not specific
• Overlap, evolving disease
• PVSG study: 281 PV patients at diagnosis
– 13% did not have increased marrow cellularity
– 11% had moderate to marked increase in reticulin
• Inadequate tool to distinguish PV from ET or PMF
Ellis JT 1986
![Page 33: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/33.jpg)
?
![Page 34: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/34.jpg)
Serum erythropoeitin
• A normal epo level does not exclude PV
• A low epo level is not specific for PV
• Epo levels do not distinguish PV from V617F-positive ET
• Erythrocytosis + presence of JAK2V617F makes epo level redundant
Casadevall N 1994
![Page 35: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/35.jpg)
Endogenous Erythroid Colony (EEC)
formation
• Only in research laboratories
• Never standardised
• Not specific; can also be observed in ET
![Page 36: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/36.jpg)
‘Realistic’ PV criteria
Major criteria
• Hct >60
• Absent bcr-abl
• JAK2V617F
Minor criteria
• BM trilineage
hyperplasia
• Palpable
splenomegaly
• Thrombocytosis >400
• Leukocytosis >12
PV diagnosis= All 3 major + 1 minor or
first 2 major + 2 minor
![Page 37: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/37.jpg)
Essential
Thrombocythaemia
![Page 38: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/38.jpg)
ET
• The only MPD without a specific
phenotype
• A diagnosis of exclusion
• JAK2V617F identifies 50% of patients with
isolated thrombocytosis as possibly having
ET
![Page 39: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/39.jpg)
WHO 2008- ET
All 4 criteria:
1. Sustained platelet ≥ 450 x 109/L
2. Megakaryocyte proliferation with large and mature morphology. No or little granulocyte or erythroid proliferation
3. Not meeting WHO criteria for CML, PV, MF, MDS
4. JAK2V617F mutation or other clonalmarker or no evidence of reactive thrombocytosis
![Page 40: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/40.jpg)
JAK2V617F in ET
• High positive predictive value for a MPD
vs. reactive states
• V617-positive thrombocythemia resembles
PV
• Higher levels of Hb & white cells and a
more cellular BM
Campbell PJ 2005
![Page 41: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/41.jpg)
Clinical Consequences of the JAK2
Mutation in ET
Age* (years) 60 (39−77) 52 (32−75) <0.0001
Hb (g/L) 145 (14) 135 (14) <0.0001
WBC† 10.6 (3.4) 9.3 (2.6) <0.0001
Neutrophils† 7.4 (3.0) 6.2 (2.2) <0.0001
Platelets† 902 (276) 1030 (343) <0.0001
Campbell PJ, Lancet 2005;366:1945-1953
JAK2V617F
n=414
JAK2 wild-type
n=362
p
![Page 42: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/42.jpg)
Primary Myelofibrosis
![Page 43: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/43.jpg)
WHO 2001- PMF
• Prefibrotic vs. fibrotic stage
• Mild vs. marked
– PMF BM changes
– Leukoerythroblastosis/ dacrocytosis
– Anaemia and/or organomegaly
– Leukothrombocytosis
![Page 44: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/44.jpg)
WHO 2008- PMF
Major criteria1. Megakaryocyte prolif
and atypia ±reticulin/collagen fibrosis
2. Not meeting WHO criteria for CML, PV, MDS
3. JAK2V617F mutation or other clonal marker or no reactive fibrosis
Minor criteria
1. Leukoerythroblastosis
2. Increased serum LDH
3. Anaemia
4. Palpable
splenomegaly
Diagnosis: all 3 major + 2 minor
![Page 45: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/45.jpg)
![Page 46: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/46.jpg)
Emphasis on megakaryocyte
atypia in BM histology
ET PMF
Thiele J 2006
Polypoid nuclei
Loose clusters
Bulbous nuclei
Dense clusters
![Page 47: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/47.jpg)
PMF
• Biopsy is essential for diagnosis
• Primary vs. idiopathic
• Presence of MF does not exclude PV or
ET
• Prefibrotic phase- not possible to identify
morphologically
• Splenomegaly- minor or major criteria?
![Page 48: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/48.jpg)
JAK2V617F in PMF
• Not specific for PMF
• Helpful in differentiating PMF from reactive
conditions
![Page 49: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/49.jpg)
Impact of V617F on
Prognosis
![Page 50: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/50.jpg)
Conflicting evidence
• Risk of thrombosis
• Risk of leukemic transformation
• Survival studies
![Page 51: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/51.jpg)
Hazard ratio
(95%CI)
p
value
Standard risk factors 1.8 (1.1-3.0) 0.04
WBC of at least 8.7 x 109/L 1.6 (0.9-2.8) 0.06
Platelet at least 784 x 109/L 0.9 (0.5-1.6) NS
JAK2V617F 1.4 (0.7-3.0) NS
Risk Factors for thrombosis in
ET Patients (n=439)
Carobbio A, Blood 2007
![Page 52: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/52.jpg)
V617F
n=414
Wt
n=362
p value
Arterial thrombosisIn year before diagnosis
After trial entry*
3825
2421
NSNS
Venous thromboembolismIn year before diagnosis
After trial entry*
1112
24
0.040.06
Major haemorrhage 18 14 NS
Death 34 23 NS
Complication Rate in JAK2-positive
ET Patients
Campbell PJ, Lancet 2005
*After entry into one of three prospective multicentre studies of high-, medium- and low-risk ET patients.
![Page 53: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/53.jpg)
V617F
n=414
Wt
n=362
p value
Myelofibrosis 7 13 NS
MDS/AML 5 2 NS
Polycythaemia vera 6 0 0.01
Rate of Transformation in
JAK2-positive ET Patients
Wt=wild type
Campbell PJ, Lancet 2005
![Page 54: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/54.jpg)
Risk factors for thrombosis in PMF
(n=707)
No. (%) Hazard
ratio
95% CI P
Age >60 393 (56) 2.34 1.24-4.39 .01
JAK2V617F 259 (37) 1.92 1.10-3.34 .02
WBC >15 162 (23) 1.72 0.97-2.72 .06
Barbui T, Blood 2010
![Page 55: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/55.jpg)
Leu
kem
ic t
ran
sfo
rmati
on
Time (months)
0 50 100 150 200
0.0
0.4
0.6
1. 0
0.8
JAK2 pos (n=86)
JAK2 neg (n=88)
Giovanni Barosi, Blood 2007
P= .02
PMF patients
![Page 56: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/56.jpg)
JAK2V617: Poorer survival in
idiopathic myelofibrosis
N= 152 idiopathic MF
N= 83 (54%) JAK2V617 positive
• Higher neutrophil count (p=.02)
• Less requirement for transfusion (p=.03)
• Poorer overall survival (p=.01)
Campbell PJ, Blood 2006
![Page 57: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/57.jpg)
Risk stratification in MPD
![Page 58: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/58.jpg)
Risk stratification
• High Risk
– Age >60
– h/o thrombosis
– ? WBC >15
– ? Presence of
JAK2V617F
• Low risk
– Age <60
– No h/o thrombosis
– ? WBC <15
– ? Absence of
JAK2V617F
Cortellazo S 1990; Landolfi R 2007
![Page 59: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/59.jpg)
Summary
• MPD is a clonal disorder/ neoplasm
• The discovery of JAK2V617F has modified
the diagnostic approach to MPD
• JAK2V617F has a high negative predictive
value in PV
![Page 60: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/60.jpg)
Summary
• JAK2V617F is useful in differentiating ET
and PMF from reactive conditions
• It is also helpful in diagnosing MPD in
Budd Chiari Syndrome where
splenomegaly and hemodilution may mask
the diagnosis
![Page 61: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/61.jpg)
Summary
• There is no single diagnostic test for MPD
• MPD diagnosis is still a clinical exercise
• Need to exclude secondary causes
• Bone marrow trephine histology is
important in diagnosis but overlap occurs
![Page 62: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/62.jpg)
Summary
• The prognostic relevance of JAK2
mutation remains inconclusive
• Does not warrant change in Rx strategies
• Need further studies
![Page 63: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/63.jpg)
![Page 64: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/64.jpg)
Don’t be
Like the clinical phenotype of MPD
which changes over time, so will
the classification
![Page 65: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/65.jpg)
We’ll stick to
Myeloproliferative Disorders
PV
PMF
ET
![Page 66: UPDATES IN THE DIAGNOSIS & CLASSIFICATION OF ...haematology.org.my/afh2010/slides/14b.pdfWHO 2008- PV Major criteria 1. Hb >18.5(M); >16.5(F) or other RCV 2. Presence of JAK2V617F](https://reader033.vdocument.in/reader033/viewer/2022051920/600ce5ec7edd6d4e361ae45a/html5/thumbnails/66.jpg)
The end